Table 3 Registered ongoing clinical trials of CAR-NK treatment for solid tumors in Clinicaltrial.org
From: Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T
Registration Time | NO. | Status | Estimated enrollment | Target | Intra-cellular main | Vector | Cell sources | Tumor Type | Country |
|---|---|---|---|---|---|---|---|---|---|
Oct-22 | NCT03692663 | recruiting | 9 | PSMA | NA | NA | NA | metastatic castration-resistant prostate cancer | China |
Sep-22 | NCT05194709 | recruiting | 20 | NKG2D-ligand | NA | NA | NK-92 cells | relapsed/refractory solid tumors | China |
Aug-22 | NCT05507593 | recruiting | 18 | DLL3 | NA | NA | NA | relapsed / refractory extensive stage small cell lung cancer | China |
Jun-22 | NCT05410717 | recruiting | 40 | CLDN6 | NA | NA | autologous PBMC | various solid tumors | China |
Feb-22 | NCT05248048 | recruiting | 9 | NKG2D-ligand | NA | NA | NA | previously treated liver metastatic colorectal cancer | China |
Jan-22 | NCT05528341 | recruiting | 38 | NKG2D-ligand | NA | NA | NA | refractory metastatic colorectal cancer | China |
Jan-22 | NCT05194709 | recruiting | 40 | Oncofetal Trophoblast Glycoprotein (5 T4) | NA | NA | NA | advanced solid tumors | China |
Nov-21 | NCT05137275 | recruiting | 56 | Oncofetal Trophoblast Glycoprotein (5 T4) | NA | NA | NA | locally advanced or metastatic solid tumors | China |
Dec-17 | NCT03383978 | recruiting | 42 | HER2 | CD3ζ | NA | NK-92 cells | recurrent or refractory HER2-positive glioblastoma | China |